Lyell Immunopharma, Inc.
LYEL · NASDAQ
Earnings history and estimates
Reported and estimated revenue, EPS and post-earnings movement.
| Period | Date | Revenue actual | Revenue estimate | EPS actual | EPS estimate | 1D move |
|---|---|---|---|---|---|---|
| 2026 Q2 | August 5, 2026 | — | — | — | — | — |
| 2026 Q1 | May 6, 2026 | 2.00K | 3.00K | -1.10 | -2.78 | — |
| 2025 Q4 | March 12, 2026 | 6.00K | 15.25K | -7.68 | -2.15 | -1.91% |
| 2025 Q3 | November 12, 2025 | 15.00K | — | -2.13 | -2.81 | -2.76% |
| 2025 Q2 | August 12, 2025 | 8.00K | 4.00K | -2.89 | -3.80 | -0.65% |
| 2025 Q1 | May 13, 2025 | 7.00K | — | -3.60 | -3.80 | — |
| 2024 Q4 | March 11, 2025 | 11.00K | — | -14.40 | -3.66 | -9.71% |
| 2024 Q3 | November 7, 2024 | 34.00K | — | -3.40 | -4.06 | +19.35% |
| 2024 Q2 | August 7, 2024 | 13.00K | 3.25K | -0.18 | -0.20 | — |
| 2024 Q1 | May 6, 2024 | 3.00K | 1.00K | -4.80 | -3.90 | -1.67% |
| 2023 Q4 | February 28, 2024 | 13.00K | 3.25K | -4.00 | -4.26 | -0.35% |
| 2023 Q3 | November 7, 2023 | 25.00K | 6.25K | -0.20 | -0.27 | — |
| 2023 Q2 | August 8, 2023 | 27.00K | 18.00K | -5.20 | -6.06 | 0.00% |
| 2023 Q1 | May 4, 2023 | 65.00K | -17.50K | -5.40 | -5.66 | +5.67% |
| 2022 Q4 | February 28, 2023 | 48.39K | 16.13M | -0.03 | -0.31 | — |
| 2022 Q3 | November 8, 2022 | 3.00K | 1.80M | -5.60 | -6.74 | +3.75% |